Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Aytu Biopharma (AYTU) over the last 16 years, with Q4 2025 value amounting to -$2.6 million.

  • Aytu Biopharma's Net Cash Flow fell 99827.59% to -$2.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $9.6 million, marking a year-over-year increase of 100782.51%. This contributed to the annual value of $10.9 million for FY2025, which is 46743.87% up from last year.
  • Per Aytu Biopharma's latest filing, its Net Cash Flow stood at -$2.6 million for Q4 2025, which was down 99827.59% from $1.7 million recorded in Q3 2025.
  • In the past 5 years, Aytu Biopharma's Net Cash Flow ranged from a high of $13.0 million in Q1 2021 and a low of -$9.4 million during Q3 2021
  • Over the past 5 years, Aytu Biopharma's median Net Cash Flow value was -$107000.0 (recorded in 2023), while the average stood at -$190150.0.
  • Examining YoY changes over the last 5 years, Aytu Biopharma's Net Cash Flow showed a top increase of 509471.54% in 2025 and a maximum decrease of 106320.35% in 2025.
  • Aytu Biopharma's Net Cash Flow (Quarter) stood at -$5.3 million in 2021, then increased by 18.05% to -$4.3 million in 2022, then surged by 89.94% to -$435000.0 in 2023, then skyrocketed by 166.67% to $290000.0 in 2024, then crashed by 998.28% to -$2.6 million in 2025.
  • Its last three reported values are -$2.6 million in Q4 2025, $1.7 million for Q3 2025, and $12.8 million during Q2 2025.